Defining Patient-Centeredness in Healthcare

Published May 21, 2018

ISPOR Special Interest Group Presents Findings and Consensus Definition for “Patient Engagement” and “Patient-Centeredness”

Baltimore, MD, USA—May 21, 2018—ISPOR, the professional society for health economics and outcomes research, held a session this evening, “Defining Patient-Centeredness and Engagement in Health Economics and Outcomes Research: Proposed Definition and Stakeholder Response [F3],” at ISPOR 2018 in Baltimore, MD, USA. Patient-related initiatives in healthcare are expanding as more and more stakeholders seek to involve patients in drug development, research, and delivery of healthcare. The lack of a common definition for the terms “patient engagement” and “patient-centeredness” has made it difficult to quantify and measure the impact of related initiatives. When these terms are employed, they are often used interchangeably and/or not defined, which can lead to misunderstanding. This lack of a consistent, clear definition for these terms has been highlighted in outcomes research, pharmacoepidemiology, and related fields, as a barrier to implementing and measuring patient engagement in the field. The session was moderated by Rachel L. Harrington, BA, University of Illinois at Chicago, Chicago, IL, USA. Speakers included Eleanor M. Perfetto, PhD, MS, National Health Council, Washington, DC, USA and University of Maryland School of Pharmacy, Baltimore, MD, USA; Suzanne Schrandt, JD, Arthritis Foundation, Atlanta, GA, USA; and Sarah Donelson, MA, Genentech, San Francisco, CA, USA. In this session, speakers presented the proposed consensus definition of “patient engagement” suitable for use in the context of health economics and outcomes research. The proposed definition was derived from a multistep process that included a systematic review and qualitative analysis of existing definitions in addition to a multistakeholder review. The speakers shared the implications of and the response to a consensus definition for patient engagement from the perspective of key stakeholders, including patients, policy/research, and industry. The ISPOR Patient-Centered Special Interest Group, comprised of researchers and patient representatives, will submit a manuscript entitled, “Defining Patient Engagement in Research: Results of a Systematic Review and Analysis,” to the Society’s journal, Value in Health. Additional information on ISPOR 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBaltimore.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×